Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Treatment Paradigms in AMD Management Part 2

By: Carl Regillo, MD; W. Lloyd Clark, MD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

Expiration Date: Wednesday, October 31, 2018

Learning Objectives

Upon completion of this activity, participants will be better able to:

Discuss the outcomes of pivotal studies in AMD, and how study results may differ from “real-world” dosing method
Identify patient subtypes (eg. RAP lesion, pigment epithelial detachments, occult lesions) that will require long-term treatment and imaging evaluation.
Develop a long term treatment plan for patients with AMD based on results from clinical trials and extension studies
Compare the extended safety outcomes of anti-VEGF therapies as published in long term studies.

Accreditation and Designation Statement

ACCREDITATION STATEMENT

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

The following faculty members have the following financial relationships with commercial interests:
Lloyd Clark, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bayer Pharmaceuticals; Genentech, Inc; Ohr Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co., Ltd. Grant/Research Support: Allergan, Inc.; Genentech, Inc and Regeneron Pharmaceuticals, Inc.

Carl Regillo, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Genentech, Inc; Iconic Therapeutics; and Notal Vision. Grant/Research Support: Alcon; Allergan, Inc.; Genentech, Inc; GlaxoSmithKline; Iconic Therapeutics; Novartis; and Regeneron Pharmaceuticals, Inc.

Editorial Support Disclosure
Cheryl Cavanaugh, MS, Evolve Medical Education LLC and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report.
Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC or Regeneron Pharmaceuticals, Inc.

Video Resources

BackNext